The role of aromatase inhibitors in early breast cancer

Current Treatment Options in Oncology

Volumn 4, Issue 2, 2003, Pages 133-140

  Chung, Cathie T ^a   Carlson, Robert W ^b  

^a STANFORD UNIVERSITY   (United States)

^b NONE

Author keywords

Aromatase Inhibitor; Breast Cancer; Letrozole; Postmenopausal Woman; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; ENZYME INHIBITOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; BREAST TUMOR; FEMALE; HUMAN; MIDDLE AGED; PATHOLOGY; REVIEW;

ADULT; AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 0038504944     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-003-0014-y     Document Type: Article

References (30)

1. Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998, 351:1451–1467. Seminal meta-analysis establishing the use of adjuvant hormonal therapy.
2. Carlson RW, Anderson BO, Bensinger W, et al.: National Comprehensive Cancer Network practice guidelines for breast cancer. Version 2, 2002. http://www.nccn.org. Accessed October 9, 2002.
3. Goldhirsch A, Glick JH, Gelber RD, et al.: Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. Seventh International Conference on adjuvant therapy of primary breast cancer. J Clin Oncol 2001, 19:3817–3827.
4. Levine M: Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-positive breast cancer (summary of the 2001 update). CMAJ 2001, 164:644–646.
5. Levine M: Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update). CMAJ 2001, 164:213.
6. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment, and follow-up of primary breast cancer. Ann Oncol 2001, 12:1047-1048.
7. Fisher B, Land S, Mamounas E, et al.: Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project Experience. Semin Oncol 2001, 28:400–418. DOI: 10.1016/S0093-7754(01)90133-2
8. Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998, 90:1371–1388. DOI: 10.1093/jnci/90.18.1371
9. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomized prevention trial. Lancet 2002, 360:817-824.
10. Veronesi U, Maisonneuve P, Costa A, et al.: Prevention of breast cancer with tamoxifen preliminary findings from the Italian randomized trial among hysterectomised women. Lancet 1998, 352:93–97.
11. Powles T, Eeles R, Ashley S, et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998, 352:98–101.
12. Gail MH, Brinton LA, Byer DP, et al.: Projecting the individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989, 81:1879–1886. DOI: 10.1093/jnci/81.24.1879
13. Chemoprevention of Breast cancer: recommendations and rationale. Ann Intern Med 2002, 137:56-58.
14. Chlebowski RT, Col N, Winer EP, et al.: American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002, 20:3328–3343. A review of breast cancer prevention trials and specific recommendations supported by the American Society of Clinical Oncology. DOI: 10.1200/JCO.2002.06.029
15. Carlson RW, Barakat R, Bevers TB, et al.: NCCN breast cancer risk reduction guideline. Version 1, 2001. http://www.nccn.org. Accessed October 24, 2002.
16. Ingle JN: Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. Oncology 2001, 15:28–34.
17. Boeddinghaus IM, Dowsett M: Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J Steroid Biochem Mol Biol 2001, 79:85–91. DOI: 10.1016/S0960-0760(01)00126-1
18. Buzdar AU, Jonat W, Howell A, et al.: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Cancer 1998, 83:1142–1152. DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7
19. Dombernowsky P, Smith I, Falkson G, et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: a double blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998, 16:453–461.
20. Kaufmann M, Bajetta E, Dirix LY, et al.: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized doubleblind trial. J Clin Oncol 2000, 18:1399–1411.
21. Buzdar A, Douma J, Davidson N, et al.: Phase III multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001, 19:3357–3366.
22. Nabholtz JM, Buzdar A, Pollak M, et al.: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2001, 18:3758–3767.
23. Mouridsen H, Gershanovich M, Sun Y, et al.: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001, 19:2596–2606.
24. Bonneterre J, Buzdar A, Nabholtz JM, et al.: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma. Cancer 2001, 92:2247–2258. DOI: 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y
25. The ATAC (arimidex, tamoxifen alone, or in combination) Trialists’ Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002, 359:2131–2139. The first report of the only published study comparing the efficacy of an aromatase inhibitor and tamoxifen as adjuvant hormonal therapy in postmenopausal women. DOI: 10.1016/S0140-6736(02)09088-8
26. Winer EP, Hudis C, Burstein HJ, et al.: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002, 20:3317–3327. An analysis of the ATAC trial and position paper of the American Society of Clinical Oncology on the use of aromatase inhibitors in patients with early breast cancer. DOI: 10.1200/JCO.2002.06.020
27. Cummings FJ: Evolving uses of hormonal agents for breast cancer therapy. Clin Ther 2002, 24(Suppl C): C3-C25. DOI: 10.1016/S0149-2918(02)85158-X
28. Zhang Z, Yamashita H, Toyama T: Semiquantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2002, 74:47–53. DOI: 10.1023/A:1016022314608
29. Smith TJ, Hillner RE: The efficacy and cost effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 1993, 11:771–776.
30. Higa GM: New generation aromatase inhibitors in breast cancer: weighing out potential costs and benefits. Pharmacoeconomics 2000, 17:121–132. DOI: 10.2165/00019053-200017020-00002